Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Google Inc (GOOG), Lennar Corporation (LEN): Billionaire Stanley Druckenmiller’s Big 5

Billionaire Stanley Druckenmiller founded his Duquesne Capital hedge fund in 1981. It now has some $10 billion in assets under management. Previously, Druckenmiller managed money for George Soros from 1988 to 2000, and was the lead portfolio manager for Soros’ famous Quantum Fund. Outlined below are Druckenmiller’s top five stocks going into the second quarter, let’s check them out (see Druckenmiller’s selloffs).
Lennar Corporation (NYSE:LEN)
Housing bets
Druckenmiller’s top stock pick is Lennar Corporation (NYSE:LEN), which makes up 8% of the hedge fund’s portfolio. Lennar is one of the largest U.S. home builders, with a focus on moderately priced homes. Lennar posted EPS of $0.26, versus $0.08 during the first quarter, on the back of a 37% revenue rise; the stock is now up over 55% for the past twelve months.
Revenues are expecte to be up some 33% in fiscal 2013, after a 33% rise in fiscal 2012. The real thesis for the expected revenue growth is an assumed continued recovery in housing. Lennar Corporation (NYSE:LEN) also has a strong positioning in southeast Florida, which is expected to grow at a quicker pace than the overall market. Lennar Corporation (NYSE:LEN) also appears to be trading relatively cheaply at only 11.5 times earnings, whereas the likes of NVR and M/I Homes trade in excess of 25 times earnings.
Druckenmiller’s third-largest holding is another homebuilder, D.R. Horton, Inc. (NYSE:DHI), and makes up 5.8% of his portfolio. Much like Lennar Corporation (NYSE:LEN), D.R. Horton, Inc. (NYSE:DHI) also posted robust EPS results last quarter, with EPS coming in at $0.32, compared to $0.13 for the same quarter last year. This comes as homebuilding revenue was up 49% and the number of homes closed was up 33%.
The future looks bright for D.R. Horton, Inc. (NYSE:DHI), coupling the continued housing recovery and the company’s contract backlog of $1.7 billion. D.R. Horton, Inc. (NYSE:DHI) also has a strong balance sheet, with over $1 billion in cash and marketable securities, which should allow the company to make strategic land acquisitions going forward.

Pharma plays

Druckenmiller’s number-two stock pick is Pfizer Inc. (NYSE:PFE) , which makes up 6.8% of the hedge fund’s portfolio. In February, Pfizer completed the IPO of 20% of its Zoetis animal health unit. Late last month, Pfizer announced plans to split off its remaining 80% interest, allowing shareholders to exchange all, some, or none of their Pfizer Inc. (NYSE:PFE) common shares for Zoetis shares. The move is expected to allow Pfizer Inc. (NYSE:PFE) to refocus on its higher-margin drug business.

Revenues for 2013 are expected to see a downfall due to ongoing generic erosion in off-patent Lipitor, Detrol and Xalatan. Yet, the company should see strength from its Lyrica muscle pain therapy (Pfizer Inc. (NYSE:PFE)’s largest-selling drug), and new oncology agents that include Sutent.

In fifth is Druckenmiller’s other pharma bet, Eli Lilly & Co. (NYSE:LLY) , making up 5.4% of Duquesne’s portfolio. Eli is one of the leading producers of prescription drugs. Eli Lilly & Co. (NYSE:LLY) posted first quarter EPS of $1.14, compared to $0.92 for the same period last year, and blowing past consensus of $1.05.

However, 2012 volumes are expected to see a decline due to Zyprexa antipsychotic, which lost U.S. patent protection in late 2011, but there should be an offset with strength in Cymbalta antidepressant and Alimta oncology.

Notable initiatives for Eli Lilly include the development of two drugs: ramucirumab for stomach cancer and empagliflozin for type 2 diabetes. The firm also has three more Phase 3 (final stage) assets to be submitted to the FDA for regulatory approval later this year. Eli Lilly & Co. (NYSE:LLY) has a total of 59 projects in its pipeline. Like Druckenmiller, billionaire Jim Simons is a big fan of pharma. Simons is the top hedge fund owner by shares of Eli Lilly & Co. (NYSE:LLY) (check out Simons’ bullish bets).

The tech bet
The tech giant, Google Inc (NASDAQ:GOOG), is Druckenmiller’s fourth-largest stock holding and makes up 5.8% of his portfolio. Revenues are expected to be up 15% in 2013 and then 16% in 2014, thanks to tailwinds from the Motorola purchase and further diffusion of its Android mobile OS.
Google Inc (NASDAQ:GOOG) I/O, its annual developer conference, revealed some key announcements for Google Inc (NASDAQ:GOOG) users. These include the introduction of a music subscription service, updates to Chrome browser, improvements to Google+, next-gen Maps, and of course there was tons of buzz surrounding Google Inc (NASDAQ:GOOG) Glass, which will be available in 2014 and could be a game changer.
There is still strength in Google Inc (NASDAQ:GOOG) ‘s core business, with search and advertising revenues expected to grow 20% in 2013 and 18% in 2014, due to growth in display advertising. Despite being up 50% over the past twelve months, Google Inc (NASDAQ:GOOG) also appears to be trading cheaply. Google trades at five times sales, compared to Baidu’s 8.6 times and Yandex’s 7.8 times.  Google Inc (NASDAQ:GOOG) is billionaire Stephen Mandel’s second-largest stock holding (check out Mandel’s top stocks).
The bottom line
Billionaire Druckenmiller loves housing and pharma, with a little tech mixed in. Both of his drug makers pay a solid dividend yield, with Pfizer Inc. (NYSE:PFE) paying 3.4% and Eli 3.67%. Meanwhile, both of the homebuilders should also perform well on the rebound in housing. I think the bets on pharma and housing are solid. I also believe that Google is worth checking out.

Marshall Hargrave has no position in any stocks mentioned. The Motley Fool recommends Google. The Motley Fool owns shares of Google. Marshall is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article Billionaire Stanley Druckenmiller’s Big 5 originally appeared on Fool.com is written by Marshall Hargrave.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...